Targeting cancer stem cells with monoclonal antibodies: a new perspective in cancer therapy and diagnosis

References

• Garcia M, Jemal A, Ward EM et al. Global Cancer Facts & Figures 2007. American Cancer Society, GA, USA, (2007).
   Google Scholar
• Brasil. Ministério da Saúde. Instituto Nacional de Câncer (2007). Estimativas 2008: Incidência de Câncer no Brasil.
   Google Scholar
• Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat. Biotechnol.23(9), 1147–1157 (2005).
   PubMed Web of Science ®Google Scholar
• Strome SE, Sausville EA, Mann D. A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. Oncologist12(9), 1084–1095 (2007).
   PubMed Web of Science ®Google Scholar
• Reichert JM, Dewitz MC. Anti-infective monoclonal antibodies: perils and promise of development. Nat. Rev. Drug Discov.5, 191–195 (2006).
   PubMed Web of Science ®Google Scholar
• Perk LR, Visser GWM, Vosjan MJWD et al.89Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals 90Y and 177Lu in tumor-bearing nude mice after coupling to the internalizing antibody Cetuximab. J. Nucl. Med.46, 1898–1906 (2005).
   PubMed Web of Science ®Google Scholar
• VanMeter A, Signore M, Pierobon M, Espina V, Liotta LA, Petricoin EF III. Reverse-phase protein microarrays: application to biomarker discovery and translational medicine. Expert Rev. Mol. Diagn.7(5), 625–733 (2007).
   PubMed Web of Science ®Google Scholar
• Dietel M. Predictive pathology of cytostatic drug resistance and new anti-cancer targets. Recent Results Cancer Res.176, 25–32 (2007).
   PubMedGoogle Scholar
• Baron A, Moore PS, Scarpa A. DNA array/microarrays in oncological research with focus on pancreatic cancer. Adv. Clin. Path.5(4), 115–120 (2001).
   PubMedGoogle Scholar
• Ailles LE, Weissman IL. Cancer stem cells in solid tumors. Curr. Opin. Biotechnol.18(5), 460–466 (2007).
   PubMed Web of Science ®Google Scholar
• Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med.3(7), 730–737 (1997).
   PubMed Web of Science ®Google Scholar
• Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA100, 3983–3988 (2003).
   PubMed Web of Science ®Google Scholar
• Singh SK, Hawkins C, Clarke ID et al. Identification of human brain tumour initiating cells. Nature432, 396–401 (2004).
   PubMed Web of Science ®Google Scholar
• Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res.65, 10946–10951(2005).
   PubMed Web of Science ®Google Scholar
• Li C, Heidt DG, Dalerba P et al. Identification of pancreatic cancer stem cells. Cancer Res.67, 1030–1037 (2007).
   PubMed Web of Science ®Google Scholar
• O’Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature445, 106–110 (2007).
   PubMed Web of Science ®Google Scholar
• Patrawala L, Calhoun T, Schneider-Broussard R et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene25, 1696–1708 (2006).
   PubMed Web of Science ®Google Scholar
• Prince ME, Sivanandan R, Kaczorowski A et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc. Natl Acad. Sci. USA104, 973–978 (2007).
   PubMed Web of Science ®Google Scholar
• Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identification and expansion of human colon-cancer-initiating cells. Nature445, 111–115 (2007).
   PubMed Web of Science ®Google Scholar
• Ouhtit A, Abd Elmageed ZY, Abdraboh ME, Lioe TF, Raj MH. In vivo evidence for the role of CD44 in promoting breast cancer metastasis to the liver. Am. J. Pathol.171(6), 2033–2039 (2007).
   PubMedGoogle Scholar
• El-Gohary YM, Silverman JF, Olson PR et al. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma. Am. J. Clin. Pathol.127(4), 572–579 (2007).
   PubMed Web of Science ®Google Scholar
• Saad RS, Liu YL, Nathan G, Celebrezze J, Medich D, Silverman JF. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer. Mod. Pathol.17(2), 197–203 (2004).
   PubMed Web of Science ®Google Scholar
• Dales JP, Garcia S, Andrac L et al. Prognostic significance of angiogenesis evaluated by CD105 expression compared to CD31 in 905 breast carcinomas: correlation with long-term patient outcome. Int. J. Oncol.24(5), 1197–1204 (2004).
   PubMed Web of Science ®Google Scholar
• Saad RS, El-Gohary Y, Memari E, Liu YL, Silverman JF. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma. Hum. Pathol.36(9), 955–961 (2005).
   PubMed Web of Science ®Google Scholar
• Dales JP, Garcia S, Bonnier P et al. CD105 expression is a marker of high metastatic risk and poor outcome in breast carcinomas. Correlations between immunohistochemical analysis and long-term follow-up in a series of 929 patients. Am. J. Clin. Pathol.119(3), 374–380 (2003).
   PubMed Web of Science ®Google Scholar
• Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin. Cancer Res.11(3), 1154–1159 (2005).
   PubMed Web of Science ®Google Scholar
• Indinnimeo M, Cicchini C, Giarnieri E, Stazi A, Mingazzini PL, Stipa V. Evaluation of CD44 variant 6 expression and clinicopathological factors in pulmonary metastases from colon carcinoma. Oncol. Rep.10(6), 1875–1877 (2003).
   PubMedGoogle Scholar
• Nair KS, Naidoo R, Chetty R. Expression of cell adhesion molecules in esophageal carcinoma and its prognostic value. J. Clin. Pathol.58(4), 343–351 (2005).
   PubMed Web of Science ®Google Scholar
• Kuriyama S, Mayor R. Molecular analysis of neural crest migration. Philos. Trans. R. Soc. Lond. B. Biol. Sci.363(1495), 1349–1362 (2008).
   PubMed Web of Science ®Google Scholar
• Okamoto OK, Oba-Shinjo SM, Lopes L, Nagahashi Marie SK. Expression of HOXC9 and E2F2 are up-regulated in CD133+ cells isolated from human astrocytomas and associate with transformation of human astrocytes. Biochim. Biophys. Acta1769(7–8), 437–442 (2007).
   PubMed Web of Science ®Google Scholar
• Jørgensen HG, Holyoake TL. Characterization of cancer stem cells in chronic myeloid leukaemia. Biochem. Soc. Trans.35(Pt 5), 1347–1351 (2007).
   PubMed Web of Science ®Google Scholar
• Hirschmann-Jax C, Foster AE, Wulf GG et al. A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proc. Natl Acad. Sci. USA101, 14228–14233 (2004).
   PubMed Web of Science ®Google Scholar
• Hadnagy A, Gaboury L, Beaulieu R, Balicki D. SP analysis may be used to identify cancer stem cell populations. Exp. Cell Res.312, 3701–3710 (2006).
   PubMed Web of Science ®Google Scholar
• Liu G, Yuan X, Zeng Z et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer.2, 5–67 (2006).
   Google Scholar
• Costello RT, Mallet F, Gaugler B et al. Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res.60, 4403–4411 (2000).
   PubMed Web of Science ®Google Scholar
• Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44+ breast cancer – initiating cells to radiation. J. Natl Cancer Inst.98, 1777–1785 (2006).
   PubMed Web of Science ®Google Scholar
• Liu G, Black KL, Yu JS. Sensitization of malignant glioma to chemotherapy through dendritic cell vaccination. Expert. Rev. Vaccines5, 233–247 (2006).
   PubMed Web of Science ®Google Scholar
• Bhalgat MK, Haugland RP, Pollack JS, Swan S. Green- and red-fluorescent nanospheres for the detection of cell surface receptors by flow cytometry. J. Immunol. Methods219, 57–68 (1998).
   PubMed Web of Science ®Google Scholar
• Pavon LF, Okamoto OK. Applications of nanobiotechnology in cancer. Einstein5, 74–77 (2007).
   Google Scholar
• Sykova E, Jendelova P. Magnetic resonance tracking of transplanted stem cells in rat brain and spinal cord. Neurodegener. Dis.3(1–2), 62–67 (2006).
   PubMed Web of Science ®Google Scholar
• Mulder WJ, Strijkers GJ, Habets JW et al. MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. FASEB J.19(14), 2008–2010 (2005).
   PubMed Web of Science ®Google Scholar
• Jin H, Hong B, Kakar SS, Kang KA. Tumor-specific nano-entities for optical detection and hyperthermic treatment of breast cancer. Adv. Exp. Med. Biol.614, 275–284 (2008).
   PubMed Web of Science ®Google Scholar
• Motoyama J, Yamashita N, Morino T, Tanaka M, Kobayashi T, Honda H. Hyperthermic treatment of DMBA-induced rat mammary cancer using magnetic nanoparticles. Biomagn. Res. Technol.6, 2 (2008).
   PubMedGoogle Scholar
• Kleiter MM, Yu D, Mohammadian LA et al. A tracer dose of technetium-99m-labeled liposomes can estimate the effect of hyperthermia on intratumoral Doxil extravasation. Clin. Cancer Res.12(22), 6800–6807 (2006).
   PubMed Web of Science ®Google Scholar
• Dritschilo A, Huang CH, Rudin CM et al. Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies. Clin. Cancer Res.12(4), 1251–1259 (2006).
   PubMed Web of Science ®Google Scholar